Nazar KARRIYEV, Sapargeldi MATNEPESOV, Mekan REJEPOV
Treatment and consultative center named after S.A.Niyazov,
Department of hospital surgery of SMUT named after M. Garryyev,
Hospital with Scientific and clinical center of cardiology
Programmed hemodialysis with permanent vascular access (PVA) remains the leading treatment method for patients with the end-stage chronic renal failure (ESRF) [1]. The effectiveness of PVA is largely determined by the adequacy of the vascular access – arteriovenous fistula (AVF). PVA should ideally ensure that the blood flow rate matches the prescribed dialysis proportion and long-term functioning without complications. Despite the fact that significant progress has been made in dialysis technology in recent years, the problems associated with providing PVA in patients with type II diabetes mellitus remain unresolved [3, 5].
